<DOC>
	<DOCNO>NCT02187276</DOCNO>
	<brief_summary>Background objective : The aim naturalistic study : analyze factor could predictive good response cholinesterase inhibitor ( ChEI ) , : age , sex , school , mild ( CDR 1 ) moderate Alzheimer 's disease ( AD ) , ( CDR 2 ) , Apoliprotein epsilon 4 ( APOE Ɛ4 ) , among others , cognitive clinical response . We also classify patient accord response Mini mental State Examination ( MMSE ) . Finally saw polymorphism APO E cytochrome P450 2D6 ( CYP2D6 ) try correlate response different allelic form Apo E among others wild type homozygote ( wt/wt ) polymorphism ( CYP2D6*3 , *4 , *5 , *6 10 ) CYP 2D6 . Patients Methods : 129 patient diagnosed AD AD+cerebrovascular disease ( CVD ) mild moderate . After 12 month-treatment , 97 patient complete study . They assess ( four ) time . In first visit , without take ChEI , 3 , 6 12 month-treatment , take donepezil rivastigmine galantamine . We also extract 5 mL blood sample genotype DNA . In visit , apply cognitive , functional , mood behavior scale . Good responder define scored &gt; 2 MMSE . Results Conclusion : In longitudinal analysis , patient mild AD good responder 3 month consider good responder 12 month . We obtain high rate good responder compare research ( 27.8 % ) . There correlation dose , APOE CYP 2D6 polymorphism , although already obtain clinical result dose dosage 5mg .</brief_summary>
	<brief_title>The Predictive Factors Good Clinical Response Cholinesterase Inhibitors Alzheimer Disease Mixed Dementia</brief_title>
	<detailed_description>Genomic DNA genotyping extracted total blood sample collect ethylenediaminetetraacetic acid ( EDTA ) ( Wizard Genomic DNA Purification Kit : Promega® , USA ) keep frozen seventy degree Celsius negative ( -70ºC ) analysis . For APOE genotyping ( allele Ɛ2 , Ɛ3 Ɛ4 ) , DNA sample amplified polymerase chain reaction ( PCR ) , follow digestion Haemophilus haemolyticus restriction endonuclease I ( HhaI ) restriction fragment length polymorphism ( RFLP ) analysis , previously describe Hixson Vernier . The CYP2D6*3 , CYP2D6*4 CYP2D6*6 allele investigate tetra-primer PCR CYP2D6*5 allele , present entire CYP2D6 gene deletion , identify long PCR reaction , accord method describe Hersberger et al . The CYP2D6*10 allele amplify PCR follow Baclig et al . RFLP analysis perform Type II restriction enzyme ( HphI ) . For analysis positive negative control include . Subjects carry Epsilon 3 , Epsilon 3 ( Ɛ3Ɛ3 ) , CYP2D6*3/4/5/6/10-nor specific mutation classify wild-type functional allele carrier . The subject carry two defective allele classify poor metabolizers ( PM ) heterozygous classify extensive metabolizers ( EM ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Late Onset Disorders</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>AD diagnosis AD CVD accord criterion National Institute Aging Alzheimer 's Association workgroup National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) Patients mild cognitive impairment ; Other type dementia , pure vascular dementia , frontotemporal dementia , dementia Lewy body , corticobasal degeneration ; Severe dementia ( CDR 3 ) Those already take ChEI , If agreement first researcher treat physician .</criteria>
	<gender>All</gender>
	<minimum_age>59 Years</minimum_age>
	<maximum_age>92 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Predictive factor response</keyword>
	<keyword>mild moderate</keyword>
	<keyword>Alzheimer disease</keyword>
	<keyword>mixed dementia</keyword>
	<keyword>APOE</keyword>
	<keyword>polymorphism CYP 2D6</keyword>
</DOC>